Nathan Denlinger: Clinical Trials

2 trials sponsored by Nathan Denlinger, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 2

Follow Nathan Denlinger: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1RecruitingNathan Denlinger182026-12-012026-10-09
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent
Phase 1RecruitingNathan Denlinger182024-01-292026-02-27

Conditions studied

Lymphoma, Large B-Cell, Diffuse (1)

Interventions

Magnetic Resonance Spectroscopy (2)  ·  Specimen Handling (2)  ·  Biopsy (1)  ·  CT-P10 (1)  ·  CTL019 chimeric antigen receptor (1)  ·  Cyclophosphamide (1)  ·  Leukapheresis (1)  ·  Rituximab (1)  ·  Whole-Body Irradiation (1)  ·  fludarabine (1)  ·  tisagenlecleucel (1)

Countries

United States (2)